Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Price:
957 USD
3.57%
Market Closed
Updated:
May 4, 2024
Regeneron Pharmaceuticals Inc
Operating Income
|
Regeneron Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
MRNA
VRTX
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Operating Income
-$4.2B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
See Also
What is Regeneron Pharmaceuticals Inc's Operating Income?
Operating Income
4.2B
USD
4.2B
USD
Based on the financial report for Dec 31, 2023, Regeneron Pharmaceuticals Inc's Operating Income amounts to 4.2B USD.
What is Regeneron Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
19%
19%
Over the last year, the Operating Income growth was -15%. The average annual Operating Income growth rates for Regeneron Pharmaceuticals Inc have been 6% over the past three years , 11% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
